Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

J Hematol Oncol. 2023 May 8;16(1):52. doi: 10.1186/s13045-023-01449-x.

Muhammad Elnaggar^{1

2}, Sarita Agte¹, Paula Restrepo^{1

2}, Meghana Ram¹, David Melnekoff^{1

2

3}, Christos Adamopoulos^{1

2}, Mark M Stevens⁴, Katerina Kappes¹, Violetta Leshchenko¹, Daniel Verina¹, Sundar Jagannath¹, Poulikos I Poulikakos^{1

2}, Samir Parekh¹, Alessandro Laganà^{5

6

7}

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴ Travera, Medford, MA, USA.
⁵ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
⁶ Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
⁷ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].

No abstract available

Publication types